Last reviewed · How we verify
PD-1 Inhibitors
PD-1 inhibitors block the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer.
PD-1 inhibitors block the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer. Used for Advanced or metastatic solid tumors (specific indication pending phase 3 results).
At a glance
| Generic name | PD-1 Inhibitors |
|---|---|
| Also known as | PD-1, immunotherapy gourp, Lenvatinib, anti-PD-1 antibodies, Sintilimab |
| Sponsor | Jiangsu Cancer Institute & Hospital |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PD-1 (programmed death receptor 1) is an immune checkpoint that normally suppresses T cell activity to prevent autoimmunity. Tumors exploit this mechanism by expressing PD-L1 and PD-L2 ligands, which bind PD-1 and inactivate tumor-infiltrating T cells. PD-1 inhibitors restore anti-tumor immunity by blocking this interaction, enabling cytotoxic T lymphocytes to mount an effective response against malignant cells.
Approved indications
- Advanced or metastatic solid tumors (specific indication pending phase 3 results)
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Rash
Key clinical trials
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (PHASE2)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection (PHASE1, PHASE2)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
- Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma (PHASE1)
- Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PD-1 Inhibitors CI brief — competitive landscape report
- PD-1 Inhibitors updates RSS · CI watch RSS
- Jiangsu Cancer Institute & Hospital portfolio CI